Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas

Autor: Pishvaian, Michael, Morse, Michael A., McDevitt, Jennifer, Norton, Jonathan D., Ren, Song, Robbie, Gabriel J., Ryan, Patricia C., Soukharev, Serguei, Bao, Haifeng, Denlinger, Crystal S.
Zdroj: In Clinical Colorectal Cancer December 2016 15(4):345-351
Databáze: ScienceDirect
Externí odkaz: